Innovation Pharmaceuticals Inc (IPIX)

[georgejjl]

Celgene is definitely interested in buying Prurisol and/or all of Innovation Pharmaceuticals!!!

Prurisol is a strong potential competitor to both Celgene's Otezla and and Revlimid, because Prurisol is a potent inhibitor to interleukin 20.

**********************************************************************

Celgene’s oral psoriasis drug, Otezla (apremilast) looks set to become a blockbuster as sales leapt in Q2.

Sales of Otezla were $242 million in Q2, a 170% increase compared with the corresponding period last year.

Otezla, approved in plaque psoriasis and psoriatic arthritis, performed the strongest in the US revenues of $217 million.

US-based Celgene is also developing Otezla in atopic dermatitis and is assessing proof-of-concept data from a completed phase 2 trial, to be announced at a later date.

For now the company’s flagship blood cancer drug, Revlimid (lenalidomide) continues to power ahead, with sales up 18% to $1.7 billion for the quarter.

Celgene revised sales forecasts for Revlimid up slightly, to $6.8 billion for the whole year, although the growth is expected to decelerate – so the strong showing from Otezla will be most welcome.

The company raised its guidance for overall product sales up a notch to $11 billion for 2016 – previous estimates were between $10.75 billion and $11 billion.

http://pharmaphorum.com/news/celgenes-otezla-course-become-blockbuster/

Prurisol is a potent inhibitor of IL-20

*************************************************************************

Circulating serum levels of IL-20 in multiple myeloma patients: its significance in angiogenesis and disease activity.

Alexandrakis MG1, Pappa CA, Kokonozaki M, Boula A, Vyzoukaki R, Staphylaki D, Papadopoulou A, Androulakis N, Tsirakis G, Sfiridaki A.
Author information
Abstract
Angiogenesis is an important hallmark in multiple myeloma (MM) pathogenesis, with the participation of various versatile molecules. Interleukin-20 (IL-20) is a pro-inflammatory cytokine with diverse angiogenic properties. Our purpose was to estimate the possible impact of IL-20 on MM angiogenesis and disease activity. We measured serum levels of IL-20 along with levels of vascular endothelial growth factor (VEGF), basic-fibroblast growth factor and angiopoietin 2 in 58 active MM myeloma patients, in 32 of them who responded to bortezomib-based therapy and in 20 controls. We also measured bone marrow microvasclular density (MVD) by immunohistochemical method. Serum levels of all cytokines and bone marrow MVD were higher in active MM patients compared to controls and responders to bortezomib-based therapy (p < 0.001 in all cases). They were also in parallel with International Staging System stages (p < 0.001 for all cases). Serum levels of IL-20 correlated positively with levels of angiogenic cytokines and bone marrow MVD (p < 0.01 for MVD, p < 0.002 for VEGF and p < 0.001 for the other cases). Our results strongly suggest that serum IL-20 concentrations participate actively in the pathophysiology of MM progression. Therefore, it could be used as an indicator of the disease progression and angiogenesis processes.
PMID: 25631632 DOI: 10.1007/s12032-015-0488-z

https://www.ncbi.nlm.nih.gov/pubmed/25631632

Good luck and GOD bless,

George